WallStreetZenWallStreetZen

NYSE: CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for CRL

Based on 12 analysts offering 12 month price targets for CHARLES RIVER LABORATORIES INTERNATIONAL INC.
Min Forecast
$280.00+20.81%
Avg Forecast
$371.92+60.47%
Max Forecast
$465.00+100.63%

Should I buy or sell CRL stock?

Based on 12 analysts offering ratings for CHARLES RIVER LABORATORIES INTERNATIONAL INC.
Strong Buy
Strong Buy
9 analysts 75%
Buy
0 analysts 0%
Hold
3 analysts 25%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

CRL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Anonymous
Morgan Stanley
Strong BuyMaintains$350.00+51.01%2022-05-05
KeyBanc
Top 10%
91
Strong BuyMaintains$300.00+29.44%2022-05-05
Wells Fargo
Bottom 32%
32
Strong BuyMaintains$325.00+40.23%2022-04-25
Jefferies
Top 3%
98
HoldDowngrades$280.00+20.81%2022-04-25
Stephens & Co.
Bottom 22%
22
Strong BuyInitiates Coverage On$377.00+62.66%2022-04-07
Citigroup
Top 5%
96
Strong BuyUpgrades$400.00+72.58%2022-02-17
Morgan Stanley
Top 3%
98
Strong BuyMaintains$430.00+85.53%2022-02-17
KeyBanc
Top 14%
87
Strong BuyMaintains$390.00+68.27%2022-02-17
UBS
Top 11%
90
Strong BuyMaintains$465.00+100.63%2021-08-17
Credit Suisse
Bottom 15%
15
HoldMaintains$385.00+66.11%2021-07-20

1 of 2

Forecast return on equity

Is CRL forecast to generate an efficient return?
Company
34.92%
Industry
52.88%
Market
32.71%
CRL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CRL forecast to generate an efficient return on assets?
Company
12.88%
Industry
15.4%
CRL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CRL earnings per share forecast

What is CRL's earnings per share in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
$11.63+38.78%
Avg 2 year Forecast
$13.41+60.02%
Avg 3 year Forecast
$15.68+87.11%
CRL's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

CRL revenue forecast

What is CRL's revenue in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
$4.0B+11.58%
Avg 2 year Forecast
$4.5B+23.89%
Avg 3 year Forecast
$5.0B+37.9%
CRL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CRL earnings growth forecast

How is CRL forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
22.89%
Industry
23.99%
Market
15.78%
CRL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
CRL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
CRL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

CRL revenue growth forecast

How is CRL forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
11.2%
Industry
9.95%
Market
9.29%
CRL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CRL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CRL vs Diagnostics & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
CRL$231.77$371.92+60.47%Strong Buy
QGEN$44.45$56.00+25.98%Buy
EXAS$54.00$113.13+109.49%Buy
SYNH$69.77$102.14+46.40%Strong Buy
DGX$140.07$152.27+8.71%Buy
View Top Diagnostics & Research Stocks

CHARLES RIVER LABORATORIES INTERNATIONAL Stock Forecast FAQ

Is CHARLES RIVER LABORATORIES INTERNATIONAL Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 12 Wall Street analysts covering (NYSE: CRL) stock is to Strong Buy CRL stock.

Out of 12 analysts, 9 (75%) are recommending CRL as a Strong Buy, 0 (0%) are recommending CRL as a Buy, 3 (25%) are recommending CRL as a Hold, 0 (0%) are recommending CRL as a Sell, and 0 (0%) are recommending CRL as a Strong Sell.

What is CRL's earnings growth forecast for 2022-2024?

(NYSE: CRL) CHARLES RIVER LABORATORIES INTERNATIONAL's forecast annual earnings growth rate of 22.89% is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 23.99%, and while it is forecast to beat the US market's average forecast earnings growth rate of 15.78%.

CHARLES RIVER LABORATORIES INTERNATIONAL's earnings in 2022 is $422,474,000.On average, 7 Wall Street analysts forecast CRL's earnings for 2022 to be $590,860,522, with the lowest CRL earnings forecast at $582,223,696, and the highest CRL earnings forecast at $596,957,105. On average, 7 Wall Street analysts forecast CRL's earnings for 2023 to be $681,293,173, with the lowest CRL earnings forecast at $648,778,062, and the highest CRL earnings forecast at $696,026,582.

In 2024, CRL is forecast to generate $796,620,205 in earnings, with the lowest earnings forecast at $775,282,164 and the highest earnings forecast at $806,273,128.

What is CRL's revenue growth forecast for 2022-2024?

(NYSE: CRL) CHARLES RIVER LABORATORIES INTERNATIONAL's forecast annual revenue growth rate of 11.2% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 9.95%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 9.29%.

CHARLES RIVER LABORATORIES INTERNATIONAL's revenue in 2022 is $3,629,523,000.On average, 6 Wall Street analysts forecast CRL's revenue for 2022 to be $205,742,815,786, with the lowest CRL revenue forecast at $204,102,936,515, and the highest CRL revenue forecast at $206,797,118,241. On average, 6 Wall Street analysts forecast CRL's revenue for 2023 to be $228,449,387,500, with the lowest CRL revenue forecast at $223,577,963,499, and the highest CRL revenue forecast at $231,436,459,244.

In 2024, CRL is forecast to generate $254,275,784,057 in revenue, with the lowest revenue forecast at $252,534,701,505 and the highest revenue forecast at $256,220,594,098.

What is CRL's forecast return on assets (ROA) for 2022-2025?

(NYSE: CRL) forecast ROA is 12.88%, which is lower than the forecast US Diagnostics & Research industry average of 15.4%.

What is CRL's Price Target?

According to 12 Wall Street analysts that have issued a 1 year CRL price target, the average CRL price target is $371.92, with the highest CRL stock price forecast at $465.00 and the lowest CRL stock price forecast at $280.00.

On average, Wall Street analysts predict that CHARLES RIVER LABORATORIES INTERNATIONAL's share price could reach $371.92 by May 5, 2023. The average CHARLES RIVER LABORATORIES INTERNATIONAL stock price prediction forecasts a potential upside of 60.47% from the current CRL share price of $231.77.

What is CRL's Earnings Per Share (EPS) forecast for 2022-2024?

(NYSE: CRL) CHARLES RIVER LABORATORIES INTERNATIONAL's current Earnings Per Share (EPS) is $8.38. On average, analysts forecast that CRL's EPS will be $11.63 for 2022, with the lowest EPS forecast at $11.46, and the highest EPS forecast at $11.75. On average, analysts forecast that CRL's EPS will be $13.41 for 2023, with the lowest EPS forecast at $12.77, and the highest EPS forecast at $13.70. In 2024, CRL's EPS is forecast to hit $15.68 (min: $15.26, max: $15.87).

What is CRL's forecast return on equity (ROE) for 2022-2025?

(NYSE: CRL) forecast ROE is 34.92%, which is considered strong.
©2022 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending StocksStock Market SectorsStock Market Industries
Analysts
Top Performing Analysts
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.